FDA Approval for JNJ's Blood Cancer Drug Reinforces Oncology Focus Amid Valuation and Litigation Concerns

What happened

The U.S. FDA has approved Johnson & Johnson's new treatment for a type of blood cancer, making it the third drug cleared under the agency's speedy review program. This aligns with JNJ's strategic pivot towards oncology, a key growth driver emphasized in the DeepValue report to offset Stelara's loss of exclusivity. Oncology sales reached $25.4 billion in 2025, supported by drugs like Darzalex and Carvykti, demonstrating JNJ's execution in this area. However, the report notes that at $216.58 per share, the stock already discounts mid-single-digit growth, leaving limited upside without a pullback. The approval, while positive, does not immediately address core risks such as talc litigation, where reserves have been cut to $3.8 billion amid rising case counts.

Implication

The new drug adds to JNJ's growing oncology pipeline, potentially enhancing long-term revenue streams and supporting the $50 billion oncology sales target by 2030. It may help sustain investor confidence as Stelara declines, but the DeepValue report indicates the stock's 46.57% appreciation over the past year has priced in much of this growth, with an attractive entry point still at $190. Investors should monitor the drug's commercial launch and its contribution to ex-Stelara growth metrics, which need to stay above 10% to justify current levels. Critical unresolved risks include talc litigation outcomes, which could force reserve increases, and drug pricing pressures from the IRA, potentially overshadowing this development. Overall, the approval is a step forward but does not eliminate the need for caution given the tight risk-reward profile.

Thesis delta

The FDA approval does not constitute a material shift in the investment thesis. It reinforces the existing narrative of oncology-driven growth but does not address key downside risks such as talc liability increases or pricing headwinds. Therefore, the recommendation to wait for a better entry point or clearer legal resolution remains unchanged.